SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Archit Organosys jumps on getting nod to incorporate new wholly owned subsidiary

26 Jul 2022 Evaluate

Archit Organosys is currently trading at Rs. 47.85, up by 6.15 points or 14.75% from its previous closing of Rs. 41.70 on the BSE.

The scrip opened at Rs. 50.00 and has touched a high and low of Rs. 50.00 and Rs. 46.75 respectively. So far 152312 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 54.80 on 06-Oct-2021 and a 52 week low of Rs. 34.10 on 02-Sep-2021.

Last one week high and low of the scrip stood at Rs. 50.00 and Rs. 39.00 respectively. The current market cap of the company is Rs. 97.88 crore.

The promoters holding in the company stood at 57.40%, while Non-Institutions held 42.60% stake in the company.

Archit Organosys has received approval to incorporate new wholly owned subsidiary namely ‘Archit Lifescience’. The proposed new company shall be engaged primarily in the business of manufacturing chemicals namely ethyl acetate, butyl acetate, propyl acetate, acetaldehyde and acetic anhydride. The board of directors at its meeting held on July 25, 2022 has approved the same.

Archit Organosys is on the forefront in the Indian Chemical Industry, producing a variety of Organic Chemicals, Pigments, Specialty Derivatives, Cosmetic Products, Adhesives & Sealants.

Archit Organosys Share Price

56.05 -0.58 (-1.02%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
SRF 2701.70
BASF India 3467.60
Tata Chemicals 732.60
Pidilite Inds. 1579.95
Deepak Nitrite 1658.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: